DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1
File version
Author(s)
Keenan, Martine
Breese, Karen J
Heppell, Jacob
Abbott, Michael
Islam, Rafiqul
Shackleford, David M
Katneni, Kasiram
Crighton, Elly
Chen, Gong
Patil, Rahul
Lee, Given
White, Karen L
Carvalho, Sandra
Wall, Richard J
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required. Despite concerted efforts over the last several years, the number of new chemical entities that are suitable for clinical development for the treatment of Leishmania remains low. Here, we describe the discovery and preclinical development of DNDI-6174, an inhibitor of Leishmania cytochrome bc1 complex activity that originated from a phenotypically identified pyrrolopyrimidine series. This compound fulfills all target candidate profile criteria required for progression into preclinical development. In addition to good metabolic stability and pharmacokinetic properties, DNDI-6174 demonstrates potent in vitro activity against a variety of Leishmania species and can reduce parasite burden in animal models of infection, with the potential to approach sterile cure. No major flags were identified in preliminary safety studies, including an exploratory 14-day toxicology study in the rat. DNDI-6174 is a cytochrome bc1 complex inhibitor with acceptable development properties to enter preclinical development for visceral leishmaniasis.
Journal Title
Science Translational Medicine
Conference Title
Book Title
Edition
Volume
15
Issue
726
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Medical biotechnology
Biomedical engineering
Persistent link to this record
Citation
Braillard, S; Keenan, M; Breese, KJ; Heppell, J; Abbott, M; Islam, R; Shackleford, DM; Katneni, K; Crighton, E; Chen, G; Patil, R; Lee, G; White, KL; Carvalho, S; Wall, RJ; et al., DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1, Science Translational Medicine, 2023, 15 (726)